1. To compare expectations of survival benefit from immunotherapy between advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS) and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of survival beyond 2 years.
Secondary Objectives:
To compare expectations of therapeutic benefit of immunotherapy between advanced NSCLC patients with poor PS and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of cure, quality of life improvement, and lower likelihood of adverse events. To qualitatively describe the priorities and preferences for information of advanced NSCLC patients with poor PS when considering immunotherapy treatment. To evaluate the associations between discrepant expectations with patients' sociodemographic and clinical characteristics. To compare patient and oncologist expectations with actual treatment outcomes and survival
Patients being considered for or within 2 months of starting immunotherapy for advanced NSCLC Patient ≥18 years of age ECOG ≥2 Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment English speaking Willing to participate in the study and sign informed consent The study will include the oncologists that treat non-small cell lung cancer
Exclusion Criteria:
Treatment for curative intent Presence of Delirium (as determined by score >13 on MDAS 46, appendix A)
